Introduction
Cystic fibrosis-related diabetes is a well-recognized complication in patients with cystic fibrosis. As patients with cystic fibrosis survive longer, the prevalence of cystic fibrosisrelated diabetes will rise (1, 2) . Cystic fibrosis-related diabetes has distinctive clinical and pathological features compared with non-cystic fibrosis-related diabetes (3) . Microvascular complications, including diabetic retinopathy, were regarded as very rare in the past in these patients (4,5) and regular screening for diabetic retinopathy is not a universal practice in cystic fibrosis clinics in the U.K. Recently, cases of diabetic retinopathy have begun to emerge, mainly in patients with cystic fibrosis-related diabetes for 10 years or more (6,7). The aim of this study was to determine cross-sectionally the prevalence of diabetic retinopathy in adult patients with cystic fibrosisrelated diabetes for 5 yr or more who were attending a national cystic fibrosis centre in the U.K.
Patients
and Methods The levels of glycosylated haemoglobin were determined by Ion Capture Assay method (Abbott Laboratories, U.S.A.). All 32 patients received insulin for their diabetes and were pancreatic insufficient, requiring pancreatic enzyme supplementation. Continuous variables were summarized with median and range. Differences between groups were tested with the Mann-Whitney test. This study has the local ethics committee's approval and written or informed consents were obtained from all patients examined.
Results
The median age of the patients examined was 27 years (range: 19-43 years) and the median duration of diabetes was 9 years (range: 5-29 years). There was an equal sex distribution.
Five patients were found to have diabetic retinopathy (see Table 1 ). The prevalence of diabetic retinopathy for patients with diabetes for 5 yr or more and 10 yr or more were 16% (five of 31 patients) and 23% (three of 13 patients), respectively. None of the eight patients who had had diabetes between 5 and 6 yr were found to have diabetic retinopathy. Glycosylated haemoglobin levels were not significantly different between the groups of patients with and without diabetic retinopathy (median HbAlc 6.2% ds 7.3%, respectively, P=O.25).
Discussion
We found a high prevalence of diabetic retinopathy in our patients with cystic fibrosis-related diabetes, particularly in those who had diabetes for 10 yr or more. In patients with insulin-dependant diabetes mellitus, tight glycaemic control delays the onset and slows the progression of clinically important retinopathy (8). This may also apply to patients with cystic fibrosis-related diabetes. No significant difference in the glycosylated haemoglobin levels was found between our patients with and without diabetic retinopathy but the number of patients studied was relatively small. It is clear from our study that cystic fibrosis-related diabetic retinopathy should no longer be regarded as rare. This complication should be screened for at least annually, by individuals experienced in the diagnosis of diabetic retinopathy, particularly in those patients with diabetes for 5 yr B. YUNG ET AL. 
